Are We Seeing Eye to Eye?
Interested in a partnership to in-license our clinical drug candidates?
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Read Press ReleaseAPX2009 Early-Stage Retina Candidate
APX2009 is a second-generation preclinical product candidate analog of APX3330. In mouse models of retinal neovascularization, APX2009 was effective in decreasing lesion size as well as improved efficacy against the Ref-1 target compared to APX3330. An intravitreal formulation could present itself as an alternative to APX3330’s oral formulation (as published in the Journal of Pharmacology and Experimental Therapeutics).
| Product Candidate | Indication | Development Stage | Anticipated Milestones | |||||
|---|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Regulatory Approval | ||||
Retina-Focused Development |
||||||||
| APX2009 Local Delivery | Retina |
Preclinical in progress
|
Phase 1 not started
|
Phase 2 not started
|
Phase 3 not started
|
Regulatory Approval not started
|
Select retinal drug delivery technology |
|